Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I study of TRXE 002 (Cantrixil) as a potential therapy for treatment-resistant cancer that has arisen within the abdomen or has metastasised there.

Next Previous
Search
Trial Profile

Phase I study of TRXE 002 (Cantrixil) as a potential therapy for treatment-resistant cancer that has arisen within the abdomen or has metastasised there.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 15 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TRXE 002 (Primary)
  • Indications Colorectal cancer; Malignant ascites; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 17 Nov 2017 According to a Kazia Therapeutics media release, Novogen changed its name to Kazia Therapeutics.
    • 17 Mar 2016 According to a Novagen media release, this trial is scheduled to begin in the second half of 2016.
    • 29 Jul 2015 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 according to a Novagen media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top